Closed Viral Vector Manufacturing Platforms Market Forecast Reveals Where Future Industry Value Will Be Created
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Closed Viral Vector Manufacturing Platforms Market Size Outlook: How Fast Will Revenue Grow Through 2030?
The market for closed viral vector manufacturing platforms recorded substantial growth during the historical period. Its value was projected to increase from $1.96 billion in 2025 to $2.22 billion in 2026, reflecting a compound annual growth rate of 13.4%. This expansion in the historic era is linked to factors such as the rising number of gene therapy clinical trials, the growing application of viral vectors in vaccine manufacturing, the broadening of research initiatives in cell and gene therapy, an intensifying regulatory emphasis on sterile production processes, and the initial uptake of closed processing technologies.
The closed viral vector manufacturing platforms market is projected to experience robust growth over the coming years, with its value anticipated to reach $3.63 billion by 2030, driven by a compound annual growth rate (CAGR) of 13.1%. This upward trajectory during the forecast period is fueled by several key factors, including the growing commercialization of gene therapies, heightened demand for large-scale viral vector supply, increased investments in advanced biomanufacturing infrastructure, expanded contract manufacturing capacity, and a greater emphasis on process standardization and automation. Key trends shaping this period involve the widespread adoption of fully closed and automated production systems, a rising need for scalable manufacturing platforms, the integration of single-use and modular components, the expansion of end-to-end closed processing workflows, and a stronger focus on regulatory compliance along with contamination control.
Download A Free Sample Report For Comprehensive Market Insights:
Closed Viral Vector Manufacturing Platforms Market Demand Drivers: What Is Fueling Industry Growth?
The expansion of the closed viral vector manufacturing platforms market is anticipated to be fueled by the increasing number of clinical trials. These trials represent carefully structured studies involving human participants, designed to evaluate the safety, effectiveness, and appropriate application of new medical therapies or interventions. A rising demand for clinical trials exists due to the greater need for innovative treatments, as the growing occurrence of chronic and complex illnesses stimulates the creation and assessment of new drugs and therapies for unmet medical requirements. This demand is supported by closed viral vector manufacturing platforms, which ensure reliable and sterile production of viral vectors, thereby guaranteeing the safety and dependability of the therapies under examination. As an illustration, December 2024 data from the Association of the British Pharmaceutical Industry (ABPI), a UK-based trade body, showed that industry-sponsored clinical trials launched in the United Kingdom increased from 411 in 2022 to 426 in 2023. Consequently, market growth for closed viral vector manufacturing platforms is being driven by this rise in clinical trials.
Closed Viral Vector Manufacturing Platforms Market Segments: Where Are The Largest Growth Opportunities?
The closed viral vector manufacturing platforms market covered in this report is segmented –
1) By Product Type: Plasmid Deoxyribonucleic Acid (DNA), Lentiviral Vectors, Adenoviral Vectors, Adeno-Associated Viral Vectors, Retroviral Vectors, Other Product Types
2) By Workflow: Upstream Processing, Downstream Processing, Fill-Finish
3) By Application: Gene Therapy, Vaccines, Cell Therapy, Other Applications
4) By End User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutes, Contract Manufacturing Organizations, Other End Users
Subsegments:
1) By Plasmid Deoxyribonucleic Acid (DNA): Supercoiled DNA, Linearized DNA, Minicircle DNA
2) By Lentiviral Vectors: Integrating Lentiviral Vectors, Non-Integrating Lentiviral Vectors
3) By Adenoviral Vectors: Replication-Deficient Adenoviral Vectors, Replication-Competent Adenoviral Vectors
4) By Adeno-Associated Viral Vectors (AAV): Single-Stranded AAV (ssAAV), Self-Complementary AAV (scAAV)
5) By Retroviral Vectors: Gamma-Retroviral Vectors, Alpha-Retroviral Vectors
6) By Other Product Types: Herpes Simplex Virus (HSV) Vectors, Vaccinia Virus Vectors, Baculovirus Vectors
Closed Viral Vector Manufacturing Platforms Market Innovation Trends: Which Developments Are Transforming The Industry?
Key players in the closed viral vector manufacturing platforms market are concentrating on creating advanced innovations, such as nitro controllers, aimed at preventing nitrogen-related stress or toxicity in cell cultures. These nitro controllers function as instruments or systems designed to track and manage nitrogen levels or reactive nitrogen species within bioprocesses, thereby maintaining ideal conditions for cell proliferation and product generation. In May 2025, Univercells Technologies, a biotechnology firm based in Belgium, unveiled the scale-X nitro controller, which is a compact and cost-efficient solution tailored for large-scale viral vector and vaccine production. This system is designed to work with 200 m² and 600 m² scale-X nitro bioreactors and accommodates both adherent and suspension cell cultures. It facilitates efficient production of AAV, lentiviral vectors, exosomes, and oncolytic viruses, while also enabling rapid scale-up, which supports the transition from research and development to commercial manufacturing in just eight months.
Closed Viral Vector Manufacturing Platforms Market Major Participants And Competitive Dynamics
Major companies operating in the closed viral vector manufacturing platforms market are Thermo Fisher Scientific Inc., Merck KGaA, Lonza Group AG, WuXi AppTec, Samsung Biologics Co. Ltd., FUJIFILM Biotechnologies, Oxford Biomedica Plc, Hillgene, Takara Bio Inc., SkyPharma Production SAS, GeneScript ProBio, Obio Technology Corp. Ltd., VectorBuilder, Charles River Laboratories Pvt. Ltd., Creative Biogene, Esco Aster Pte. Ltd., Karma Biotechnologies, Cell and Gene Therapy Catapult, CoJourney, Applied Biological Laboratories Inc., CEVEC Pharmaceuticals, Genesail Biotech Co. Ltd.
Access The Complete Closed Viral Vector Manufacturing Platforms Market Report:
Closed Viral Vector Manufacturing Platforms Market Regional Outlook: Where Are The Largest Opportunities Located?
North America was the largest region in the Closed Viral Vector Manufacturing Platforms market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the closed viral vector manufacturing platforms market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
